Thelansis’s "Sickle Cell Disease (SCD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sickle Cell Disease treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
Sickle cell disease (SCD) is an autosomal recessive hemoglobinopathy caused by a glutamic acid to valine substitution at position 6 of the beta-globin chain, yielding abnormal hemoglobin S that polymerizes under deoxygenated conditions to drive erythrocyte sickling, hemolytic anemia, and vaso-occlusion. Hallmarks include severe episodic vaso-occlusive crises (VOCs), acute chest syndrome, stroke, and cumulative multiorgan damage. Diagnosis is established via universal newborn screening using hemoglobin electrophoresis or HPLC. Hydroxyurea remains the foundational oral disease-modifying standard of care to elevate fetal hemoglobin, supplemented by oral L-glutamine to reduce oxidative stress. Crucially, the pharmaceutical toolkit has contracted significantly due to safety and efficacy failures: both the polymerization inhibitor voxelotor and the P-selectin inhibitor crizanlizumab have been completely withdrawn from global markets. Conversely, the curative space has been fundamentally transformed. Alongside traditional matched allogeneic stem cell transplantation, two landmark genetic therapies are approved for severe phenotypes: lovotibeglogene autotemcel (Lyfgenia), a lentiviral gene-addition therapy, and exagamglogene autotemcel (Casgevy), a CRISPR-Cas9 gene-editing platform targeting BCL11A to restore functional fetal hemoglobin. These molecular therapies yield near-complete elimination of VOCs, radically rewriting the long-term prognosis.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Sickle Cell Disease (SCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report
Our team will get in touch with you shortly about the Sickle Cell Disease (SCD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036 report.